Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 10, 2011, Pages 2953-2957

  Yun, Hyejin ^a   Heo, Hye Young ^a   Kim, Hyun Ha ^a   DooKim, Nam ^b   Seol, Wongi ^a  

^a Inje University   (South Korea)

^b AmorePacific Corporation   (South Korea)

Author keywords

LRRK2; LRRK2 kinase inhibitors; Parkinson's disease

Indexed keywords

4 [[2 (4 METHYLQUINOLIN 2 YL)HYDRAZONO]METHYL]BENZENE 1,2 DIOL; [4 METHYL 2 [2 (PYRIDIN 4 YLMETHYLENE)HYDRAZINYL]QUINOLINE]; ALANINE; LEUCINE RICH REPEAT KINASE 2; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HYDROGEN BOND; IC 50; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS;

ANIMALS; CELL LINE; CELL SURVIVAL; DRUG DESIGN; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDROGEN BONDING; INHIBITORY CONCENTRATION 50; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SMALL MOLECULE LIBRARIES;

EID: 79955567288     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.03.061     Document Type: Article

References (29)

1. K.R. Chaudhuri, D.G. Healy, and A.H. Schapira Lancet Neurol. 5 2006 235
2. L.M. de Lau, and M.M. Breteler Lancet Neurol. 5 2006 525
3. T. Hatano, S. Kubo, S. Sato, and N. Hattori J. Neurochem. 111 2009 1075
4. M. Funayama, K. Hasegawa, H. Kowa, M. Saito, S. Tsuji, and F. Obata Ann. Neurol. 51 2002 296
5. C. Paisan-Ruiz, S. Jain, E.W. Evans, W.P. Gilks, J. Simon, M. van der Brug, A. Lopez de Munain, S. Aparicio, A.M. Gil, N. Khan, J. Johnson, J.R. Martinez, D. Nicholl, I.M. Carrera, A.S. Pena, R. de Silva, A. Lees, J.F. Marti-Masso, J. Perez-Tur, N.W. Wood, and A.B. Singleton Neuron 44 2004 595
6. A. Zimprich, S. Biskup, P. Leitner, P. Lichtner, M. Farrer, S. Lincoln, J. Kachergus, M. Hulihan, R.J. Uitti, D.B. Calne, A.J. Stoessl, R.F. Pfeiffer, N. Patenge, I.C. Carbajal, P. Vieregge, F. Asmus, B. Muller-Myhsok, D.W. Dickson, T. Meitinger, T.M. Strom, Z.K. Wszolek, and T. Gasser Neuron 44 2004 601
7. S. Lesage, S. Janin, E. Lohmann, A.L. Leutenegger, L. Leclere, F. Viallet, P. Pollak, F. Durif, S. Thobois, V. Layet, M. Vidailhet, Y. Agid, A. Durr, A. Brice, A.M. Bonnet, M. Borg, E. Broussolle, P. Damier, A. Destee, M. Martinez, C. Penet, O. Rasco, F. Tison, C. Tranchan, and M. Verin Arch. Neurol. 64 2007 425
8. W.P. Gilks, P.M. Abou-Sleiman, S. Gandhi, S. Jain, A. Singleton, A.J. Lees, K. Shaw, K.P. Bhatia, V. Bonifati, N.P. Quinn, J. Lynch, D.G. Healy, J.L. Holton, T. Revesz, and N.W. Wood Lancet 365 2005
9. D.G. Healy, M. Falchi, S.S. O'Sullivan, V. Bonifati, A. Durr, S. Bressman, A. Brice, J. Aasly, C.P. Zabetian, S. Goldwurm, J.J. Ferreira, E. Tolosa, D.M. Kay, C. Klein, D.R. Williams, C. Marras, A.E. Lang, Z.K. Wszolek, J. Berciano, A.H. Schapira, T. Lynch, K.P. Bhatia, T. Gasser, A.J. Lees, and N.W. Wood Lancet Neurol. 7 2008 583
10. J. Nichols, N. Dzamko, N.A. Morrice, D.G. Campbell, M. Deak, A. Ordureau, T. Macartney, Y. Tong, J. Shen, A. Prescott, and D.R. Alessi Biochem. J. 430 2010 393
11. B. Lovitt, E.C. Vanderporten, Z. Sheng, H. Zhu, J. Drummond, and Y. Liu Biochemistry 49 2010 3092
12. M. Liu, B. Dobson, M.A. Glicksman, Z. Yue, and R.L. Stein Biochemistry 49 2010 2008
13. J.P. Covy, and B.I. Giasson Biochem. Biophys. Res. Commun. 378 2009 473
14. R.J. Nichols, N. Dzamko, J.E. Hutti, L.C. Cantley, M. Deak, J. Moran, P. Bamborough, A.D. Reith, and D.R. Alessi Biochem. J. 424 2009 47
15. L. Pedro, J. Padros, L. Beaudet, H.D. Schubert, F. Gillardon, and S. Dahan Anal. Biochem. 404 2010 45
16. 4, 2 mM DTT] and incubating the mixture at 30 °C for 10 min. When indicated, 1 μg of MBP (myelin basic protein) was added as general kinase substrate. To test the compounds' inhibitory effects on LRRK2 kinase activity, each chemical was prepared at 10 mM stock in dimethyl sulfoxide (DMSO) and added to the reaction mixture at the indicated concentration. Then, the whole mixture was subjected to the protein gel electrophoresis, and levels of the LRRK2 autophosphorylation or MBP phosphorylation were analyzed by an image analyzer (Typhoon 9200, GE healthcare).
17. 50s were calculated from the formula.
18. L.J. Reichling, and S.M. Riddle Biochem. Biophys. Res. Commun. 384 2009 255
19. J. Galceran, K. de Graaf, F.J. Tejedor, and W. Becker J. Neural. Transm. Suppl. 67 2003 139
20. B. Hammerle, C. Elizalde, J. Galceran, W. Becker, and F.J. Tejedor J. Neural. Transm. Suppl. 67 2003 129
21. B.D. Lee, J.H. Shin, J. Vankampen, L. Petrucelli, A.B. West, H.S. Ko, Y.I. Lee, K.A. Maguire-Zeiss, W.J. Bowers, H.J. Federoff, V.L. Dawson, and T.M. Dawson Nat. Med. 16 2010 998
22. The kinas profiling test was performed by Milipore Co. The detail information can be found in its website, www.millipore.com/drugdiscovery/ KinaseProfiler.
23. A.B. West, D.J. Moore, S. Biskup, A. Bugayenko, W.W. Smith, C.A. Ross, V.L. Dawson, and T.M. Dawson Proc. Natl. Acad. Sci. U.S.A. 102 2005 18642
24. H.Y. Heo, J.M. Park, C.H. Kim, B.S. Han, K.S. Kim, and W. Seol Exp. Cell Res. 316 2010 649
25. 27 and relative cell survival rates were calculated. To test compounds' inhibitory activities, the indicated concentration of chemicals or an equal volume of dimethyl sulfoxide (DMSO) were treated at 1 h before the treatment of hydrogen peroxide.
26. To construct a homology model structure of the LRRK2 kinase domain, we used a crystal structure of transforming growth factor-beta (TGF-β) activated kinase 1 (TAK1) (PDB accession code: 2EVA ). The sequence alignment of LRRK2 and template proteins was generated using the FASTA program (http://www.ebi.ac.uk/Tools/fasta33 ). A 3D model structure of LRRK2 was built by using the HOMOLOGY module of Insight II program (Accelrys Software Inc., San Diego, USA) and was further refined by using the Discover 2.98 of the Insight II.
27. F.L. Baker, G. Spitzer, J.A. Ajani, W.A. Brock, J. Lukeman, S. Pathak, B. Tomasovic, D. Thielvoldt, M. Williams, C. Vines, and P. Tofilon Cancer Res. 46 1986 1263
28. M. Manthorpe, R. Fagnani, S.D. Skaper, and S. Varon Brain Res. 390 1986 191
29. G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, and A.J. Olson J. Comput. Chem. 30 2009 2785